Ironwood Pharmaceuticals (IRWD) : Mizuho Securities Usa added new position in Ironwood Pharmaceuticals during the most recent quarter end. The investment management firm now holds 23,500 shares of Ironwood Pharmaceuticals which is valued at $254,740 , the company said in a statement filed on Apr 21, 2016 with the SEC.Ironwood Pharmaceuticals makes up approximately 0.06% of Mizuho Securities Usa’s portfolio.
Ironwood Pharmaceuticals opened for trading at $10.12 and hit $10.74 on the upside on Wednesday, eventually ending the session at $10.49, with a gain of 2.34% or 0.24 points. The heightened volatility saw the trading volume jump to 37,28,628 shares. Company has a market cap of $1,504 M.
Other Hedge Funds, Including , Next Financial Group Inc reduced its stake in IRWD by selling 300 shares or 75.0% in the most recent quarter. The Hedge Fund company now holds 100 shares of IRWD which is valued at $1,084.
On the company’s financial health, Ironwood Pharmaceuticals reported $-0.10 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Feb 18, 2016. Analyst had a consensus of $-0.16. The company had revenue of $53.30 million for the quarter, compared to analysts expectations of $45.94 million. The company’s revenue was up 40.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.27 EPS.
Many Wall Street Analysts have commented on Ironwood Pharmaceuticals. Ironwood Pharmaceuticals was Initiated by Goldman to “Neutral” on Mar 21, 2016. Shares were Reiterated by Wedbush on Feb 19, 2016 to “Neutral” and Lowered the Price Target to $ 9 from a previous price target of $10 .
Ironwood Pharmaceuticals Inc. is a pharmaceutical company. The Company has a product linaclotide which is available in the United States and Mexico under the brand name LINZESS and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.